Abstract Secondary autoimmune diseases (2ndADs), most frequently autoimmune
cytopenias (AICs), were first described after allogeneic hematopoietic stem cell …

Patients undergoing autologous hematopoietic stem cell transplantation (auto-HSCT) for
autoimmune disease may have an added propensity to develop a second autoimmune …

Background and Objectives Autologous hematopoietic stem cell transplantation (aHSCT) is
increasingly used to treat aggressive forms of multiple sclerosis (MS). This procedure is …

Multiple sclerosis (MS) is a central nervous system (CNS) disorder, which is mediated by an
abnormal immune response coordinated by T and B cells resulting in areas of inflammation …

Autologous haematopoietic stem cell transplantation (AHSCT) is a vital therapeutic option
for patients with highly active multiple sclerosis (MS). Rates of remission suggest AHSCT is …

High dose immunosuppression followed by autologous hematopoietic stem cell
transplantation (AHSCT) induces prolonged clinical remission in multiple sclerosis (MS) …

Autologous haematopoietic stem-cell transplantation (AHSCT) has been experimented as a
treatment in patients affected by severe forms of multiple sclerosis (MS) who failed to …

Multiple sclerosis is an inflammatory T cell-mediated autoimmune disease. In a Phase II
clinical trial, high-dose immunosuppressive therapy combined with autologous CD34+ …

Autologous hematopoietic stem cell transplantation (aHSCT) is a highly effective treatment
of multiple sclerosis (MS). It depletes autoreactive cells and subsequently renews adaptive …

Objective Autologous haematopoietic stem cell transplantation (AHSCT) has the potential to
induce sustained periods of disease remission in multiple sclerosis (MS), which is an …